The company's consolidated net profit after tax rose to 23.76 billion rupees ($285.37 million) for the quarter ended Sept. 30
PHOTO
Sun Pharmaceutical Industries, India's largest drugmaker by revenue, reported a 5% rise in second-quarter profit on Wednesday, driven by strong sales of its generic version of popular cancer drug Revlimid.
The company's consolidated net profit after tax rose to 23.76 billion rupees ($285.37 million) for the quarter ended Sept. 30, from 22.62 billion rupees a year earlier.
($1 = 83.2601 Indian rupees) (Reporting by Rishika Sadam in Hyderabad; Editing by Sonia Cheema)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
